We tested in a translational approach the usefulness of plasma creatine kinase (CK) as an objective biomarker for levodopa-induced dyskinesia (LID). Plasma CK levels were measured in five dyskinetic parkinsonian non-human primates (NHP) and in ten PD patients with LID who participated in a treatment trial with simvastatin. Plasma CK levels were increased in dyskinetic NHP and correlated with LID severity while they were not affected by LID severity in PD patients.
CITATION STYLE
Delamarre, A., Tison, F., Li, Q., Galitzky, M., Rascol, O., Bezard, E., & Meissner, W. G. (2019). Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease. Journal of Neural Transmission, 126(6), 789–793. https://doi.org/10.1007/s00702-019-02015-x
Mendeley helps you to discover research relevant for your work.